Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(Augusta University Health), Alfonso Quintás‐Cardama(Instituto de Investigación Sanitaria La Fe), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Stefan Faderl(Jazz Pharmaceuticals (United States)), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Jenny Shan, Susan O’Brien(The University of Texas MD Anderson Cancer Center), Mary Beth Rios(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Elias Jabbour(McGill University Health Centre), Moshe Talpaz(University of Michigan)
Cited by 340
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k